Evidence map›Paper›PMID 42549279›Full record

ReviewTaiwan journal of ophthalmology

The prevalence, progression, and visual loss associated with myopic macular degeneration in Asia.

Kai-Xiong Cheong, Weizhong Lan, Quan V Hoang, Seang-Mei Saw

Abstract readReview
In one paragraph

Review in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kai-Xiong CheongSingapore Eye Research Institute, Singapore National Eye Centre, Singapore.
Weizhong LanAier Academy of Ophthalmology, Central South University, Hunan, China.
Quan V HoangSingapore Eye Research Institute, Singapore National Eye Centre, Singapore.
Seang-Mei SawSingapore Eye Research Institute, Singapore National Eye Centre, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This systematic review examines the epidemiology, natural history, and visual outcomes of myopic macular degeneration (MMD) in Asia. MMD is irreversible, may affect both eyes, and may occur during a person's productive years, making it a significant public health concern. Population-based studies report a wide variation in MMD prevalence, ranging from 0.24% in rural India to 4.5% in mainland China. MMD is etiologically heterogeneous, with its prevalence associated with a more negative spherical equivalent (SE), longer axial length (AL), older age, and a lower education level. The development of MMD is likely nonlinear, with the prevalence of MMD increasing markedly once specific thresholds in age (60-70 years), SE (-6 to - 7 diopters), and AL (about 26 mm) are exceeded. The 5-year, 6-year, and 12-year incidence of MMD is up to 1.1%, 1.2%, and 10.3% respectively. The 10-year progression rate of MMD may reach 35.5%, often involving the development or worsening of chorioretinal atrophy. MMD is associated with significant visual impairment (VI) and blindness, with a decrease in best corrected visual acuity (BCVA) ranging from one to 13 lines. Among individuals with MMD, up to 54.5% experience VI, and up to 14.9% develop blindness in the better eye. Up to 36.4%, 21.6%, 12.3%, and 4.5% of individuals with MMD have unilateral VI, bilateral VI, unilateral blindness, and bilateral blindness, respectively. BCVA loss increases with MMD severity. These findings underscore the urgent need for public health strategies to address the growing burden of MMD in Asia's aging and increasingly myopic populations.

Indexed as

Asiaepidemiologymyopic macular degenerationrisk factorsvisual outcome

Identifiers

PMID42549279
PMCPMC13431223

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.